Inotuzumab ozogamicin

Generic Name
Inotuzumab ozogamicin
Brand Names
Besponsa
Drug Type
Biotech
Chemical Formula
-
CAS Number
635715-01-4
Unique Ingredient Identifier
P93RUU11P7
Background

Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (Gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting ...

Indication

Indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL).

Associated Conditions
Refractory B-cell precursor acute lymphoblastic leukemia, Relapsed B cell precursor Acute lymphoblastic leukemia
Associated Therapies
-

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Phase 2
Completed
Conditions
Interventions
First Posted Date
2011-06-01
Last Posted Date
2017-04-13
Lead Sponsor
Pfizer
Target Recruit Count
72
Registration Number
NCT01363297
Locations
🇺🇸

Stanford Unversity Cancer Clinical Trials Office, Palo Alto, California, United States

🇺🇸

Stanford Cancer Institute, Stanford, California, United States

🇺🇸

Stanford Unversity Hospital and Clinics, CTRU, Palo Alto, California, United States

and more 12 locations

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

First Posted Date
2010-11-02
Last Posted Date
2019-01-08
Lead Sponsor
Pfizer
Target Recruit Count
338
Registration Number
NCT01232556
Locations
🇺🇸

Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services, Los Angeles, California, United States

🇺🇸

University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States

🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

and more 165 locations

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

First Posted Date
2007-11-26
Last Posted Date
2018-01-09
Lead Sponsor
Pfizer
Target Recruit Count
29
Registration Number
NCT00562965
Locations
🇺🇸

Wenatchee Valley Medical Center, Wenatchee, Washington, United States

🇺🇸

Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States

🇺🇸

Facey Medical Group, Mission Hills, California, United States

and more 34 locations

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2006-03-06
Last Posted Date
2018-03-08
Lead Sponsor
Pfizer
Target Recruit Count
119
Registration Number
NCT00299494
Locations
🇺🇸

Emory University Hospital, Atlanta, Georgia, United States

🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Northwestern Medical Faculty Foundation, Chicago, Illinois, United States

and more 33 locations
© Copyright 2024. All Rights Reserved by MedPath